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Generalized pustular psoriasis (GPP) is a rare but
serious inflammatory skin disease that may be
caused by deficiency of interleukin-36 receptor
antagonist in which there is presence of homozy-
gous or compound heterozygous mutations of the
IL-36RN gene. Most GPP cases are sporadic,
although some may be autosomal recessive.1 A
significant proportion of GPP without psoriasis
vulgaris (PV) had homozygous or compound het-
erozygous mutations in IL-36RN. GPP alone is a
distinct subtype and is etiologically distinguished
from GPP with PV. Most GPP alone is caused by
deficiency of the IL-36RN caused by IL-36RN
mutations, in contrast to GPP associated with PV,
in which this mutation is usually absent.2CASE REPORT
A 20-year-old Chinese Indonesian woman pre-
sented to our clinic in February 2014 with eryth-
roderma and pustules on the trunk, limbs, and
nails. (Fig 1, A and B) The generalized erythema
with crusting and pustules started from the age of
17 months and comes in waves with periods of
exacerbation and quiescence. There was no family
history of psoriasis. There was limited response to
topical steroids, acitretin, and ustekinumab. She
was administered pulsed methylprednisolone for
many years by her previous doctors, which led to
secondary adrenal insufficiency. She is taking reg-
ular hydrocortisone tablets, 10 mg in the morning
and 5 mg in the afternoon. Skin biopsy results from
the shin were consistent with pustular psoriasis
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her parents and sent for genetic analysis for muta-
tions of IL-36RN. Our patient carries a homozygous
pathogenic splice mutation of the IL-36 gene with
IVS3C[T (Fig 3). Her parents did not carry any
mutations of the IL-36 gene.
We initially planned to treat the psoriasis with the
recombinant interleukin-1 receptor antagonist, ana-
kinra. In view of the high treatment cost, she
declined anakinra treatment.
She has responded well to methotrexate, 7.5 mg/
week; calcitriol ointment twice daily to the face, shin,
and neck plaques; and betamethasone valerate,
0.05% cream twice daily, to the rest of the shins
and trunk.
DISCUSSION
Our patient has a de novo mutation of the IL-
36RN, as neither of her parents was heterozygous
for the mutation. To the best of our knowledge, this
is the first reported case of homozygous splice
mutation of IVS3C[T causing GPP clinically. She
had a change of nucleotide in which cytosine
pyrimidine was substituted with thymine pyrimi-
dine at intron 3. The mutation impairs the splicing
of introns from the mRNA of the IL-36RN gene and
results either in an aberrant or absence of the IL-
36RA protein. It did not lead to a change of aminoJAAD Case Reports 2015;1:51-3.
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Fig 2. Skin biopsy results showed acanthosis, elongated rete processes, spongiosis, and focal
parakeratosis. Neutrophils migrate through the epidermis and concentrate in the parakeratotic
layer. It has perivascular inflammation and includes neutrophils, lymphocytes, plasma cells,
and some eosinophils. Extravasation of red blood cells is noted in the papillary dermis.
(Hematoxylin-eosin stain; original magnification: 340.)
Fig 1. A, Scattered discrete pustules on erythematous skin on the shins. B, Dystrophic toenails
with pustules on both feet.
Fig 3. Homozygous point mutation in which the cytosine pyrimidine was substituted with the
thymine pyrimidine in the splicing donor site on the region of exon 3.
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the effect is more drastic than a change in amino
acid.
The IL-36RN antagonist and the additional 3
agonists, interleukin-36a, interleukin-36b, and inter-
leukin-36g, are expressed in epithelial tissues such as
the skin.3 Interleukin-36RN inhibits downstream
inflammatory signaling (nuclear factor k-light-
chain-enhancer of activated B cells and mitogen-
activated protein kinases), avoiding excessive
inflammatory responses.4 Dysregulation of the inter-
leukin-36einterleukin-36RN signaling pathway is a
predisposing factor GPP development.
The interleukin-1 family consists of 11 members
of which IL-36RN shares 44% homology with
interleukin-1 receptor antagonist (IL-1RA). IL-36RA
(interleukin-36 receptor antagonist) is a product of
IL-36RN, which downregulates both interleukin-1a
and interleukin-1b.5
Some of the reported homozygous IL-36RN
mutations include p.His32Arg, p.Pro76Leu, or
p.Ser113Leu, and compound heterozygous muta-
tions include p.Ser113Leu and p.Arg48Trp,
p.Glu94X, or p.Pro76Leu. These stop and missense
mutations can destabilize the IL-36RA protein
through changes to the protein structures and their
ability to bind to receptors.6
Previous case reports have shown successful
treatment of GPP with anakinra, although the high
cost for long-term anakinra is likely to be prohib-
itory to many patients, especially in developing
countries. Although some case reports show poor
response to methotrexate,7,8 our patient has
improved significantly with low doses of
methotrexate.CONCLUSION
We present a new de novo homozygous splice
mutation of IL-36RN that has not been described in
the literature. The patient’s condition is currently
well controlled with methotrexate. We highlight that
methotrexate can be considered an alternative in
patients who are unsuitable or unable to afford the
cost of anakinra.
The authors thank Dr Asma Smahi, MD, for her help
with the mutation analysis.
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